Posted in Regulatory Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy April 21, 2026 Pharmaceutical Business Review The application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility. RegulatoryOncologyRead full story